300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
Oman
LATAM
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Paraguay
Seychelles
Botswana
Canada
Ireland
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
ProQuest Investments, VC Fund

ProQuest Investments

VC Fund

Princeton, United States

ProQuest Investments is a VC fund in Princeton focused on Health Care and Biotechnology. Founded in 1998, ProQuest Investments is a healthcare venture capital firm with over $875 million under management. We have 12 deal professionals and three offices, our headquarters in Princeton, and additional offices in San Diego and Montreal. We invest in healthcare companies seeking financings ranging from seed to late-stage. Our portfolioreflects the rich diversity of the healthcare industry and exemplifies our commitment to fostering the growth of exceptional businesses. In addition to our breadth of experience across many sectors of the healthcare industry, we have special expertise in therapeutics, where innovations in drug discovery technologies and molecular analysis are transforming an enormous unmet medical need. With a proven superior track record and over 40 investments in such diverse therapeutic categories as oncology, pain and infectious disease, ProQuest Investments seeks to build long term, mutually beneficial partnerships with outstanding entrepreneurs. At the end of 2006, ProQuest Investments closed its fourth fund of $425 million.

Total investments:
37
Last investment:
Lead investor:
24%

Last updated:

Industries ProQuest Investments invests in

Health CareBiotechnologyMedicalTherapeuticsPharmaceutical

Stages ProQuest Investments invests in

Series BFunding RoundSeries ASeries CSeries D

Countries ProQuest Investments invests in

United StatesSwitzerland

Contacts

NameEmailPhoneSocials
Alain Schreiber Alain Schreiber
Jay Moorin Jay Moorin
Pasquale DeAngelis Pasquale DeAngelis
Steven Ratoff

Sign up to unlock verified contacts

Unlock Contacts

Investment Focus

Industry

  • Health Care 18 (49%)
  • Biotechnology 17 (46%)
  • Medical 7 (19%)
  • Therapeutics 7 (19%)
  • Pharmaceutical 7 (19%)
See all 12 industries →

Stage

  • Series B 8 (22%)
  • Funding Round 7 (19%)
  • Series A 6 (16%)
  • Series C 4 (11%)
  • Series D 3 (8%)
See all 8 stages →

Country

  • United States 20 (54%)
  • Switzerland 1 (3%)

Team

NameTitleInvestmentsLinksEmail
Alain Schreiber
Alain Schreiber Partner
Partner Total investments: 15
Find email
Jay Moorin
Jay Moorin Partner
Partner Total investments: 5 Find email
Pasquale DeAngelis
Pasquale DeAngelis CFO, Administrative Partner
CFO, Administrative Partner Total investments: 0 Find email
Steven Ratoff Venture Partner
Venture Partner Total investments: 0 Find email

Investments

CompanyDescriptionRoundLinks
SomaLogic SomaLogic
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. $200M / Jan 03, 2018
ReVision Optics ReVision Optics
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. $32M / Nov 10, 2016
Agile Therapeutics Agile Therapeutics
Agile Therapeutics, Inc., a specialty pharmaceutical company, engages in the development of women's healthcare products. It offers a low estrogen dose seven-day transdermal contraceptive patch system that delivers a combination of levonorgestrel and Ethinylestradiol. The company was founded in 1997 as Levotech, Inc. and changed its name toAgile Therapeutics, Inc. in April 2001. It is based in Princeton, New Jersey. $20M / Post-IPO Equity / Feb 06, 2015
SomaLogic SomaLogic
SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscantechnology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado. $16.5M / Nov 17, 2014
Mevion Medical Systems Mevion Medical Systems
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. $200M / Private Equity / Aug 04, 2014
Telormedix Telormedix
Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and autoimmune diseases. $6.8M / Series B / Dec 02, 2013
Immune Design Immune Design
Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-basedproducts for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence $49M / Series C / Oct 30, 2013
ReVision Optics ReVision Optics
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. $55M / Series E / Jul 29, 2013
Mevion Medical Systems Mevion Medical Systems
Mevion Medical Systems, Inc. (formerly Still River Systems, Inc.) is a radiation therapy company dedicated to advancing the treatment of cancer. As the pioneering developer of modern proton therapy systems, Mevion provides innovative, safe, and effective solutions by transforming advances in medical technology and science into practical clinicalreality.Mevion’s flagship product, the MEVION S250 Proton Therapy System, is designed to preserve all of the treatment benefits of traditional proton therapy systems while removing the obstacles of size, cost, and complexity. Realizing this vision, Mevion has forever changed the economics and accessibility of proton therapy worldwide.Founded in 2004, Mevion is a privately held company headquartered in the Boston metropolitan area with international offices in the United Kingdom and Japan. $55M / Private Equity / Jun 25, 2013
ReVision Optics ReVision Optics
ReVision Optics, Inc. designs, manufactures, and delivers implantable products for the treatment of presbyopia. It offers PRESBYLENS Corneal Inlay, a refractive surgery solution to correct vision lost by the natural aging process called presbyopia. The company serves the ophthalmology professionals. ReVision Optics, Inc. was formerly known asIntraLens Vision, Inc. and changed its name to ReVision Optics, Inc. in 2005. The company was founded in 1996 and is based in Lake Forest, California. $15M / Series E / Apr 16, 2013
See all 37 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
CleanTech
Big Data
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Film
Oil and Gas
Retail
Payments
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Art
Real Estate
Sporting Goods
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Sustainability
Hardware
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
Oman
LATAM
Puerto Rico
Poland
Cameroon
Guernsey
Colombia
China
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Paraguay
Seychelles
Botswana
Canada
Ireland
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does ProQuest Investments invest in?

ProQuest Investments invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Funding Round stage. Most of the 37 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

How do I contact ProQuest Investments?

Public channels for ProQuest Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at ProQuest Investments?

The team at ProQuest Investments includes Alain Schreiber (Partner), Jay Moorin (Partner) and Pasquale DeAngelis (CFO, Administrative Partner). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
ProQuest Investments ProQuest Investments Find emails